Assessment of agonist and antagonist effects of tramadol in opioid-dependent humans

Experimental and Clinical Psychopharmacology

Volumn 14, Issue 2, 2006, Pages 109-120

  Carroll, C Patrick ^a   Walsh, Sharon L ^a   Bigelow, George E ^a   Strain, Eric C ^a   Preston, Kenzie L ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Opioid agonist; Opioid withdrawal; Tramadol

Indexed keywords

HYDROMORPHONE; METHADONE; MU OPIATE RECEPTOR AGONIST; NALOXONE; NALTREXONE; OPIATE; PLACEBO; TRAMADOL;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MAINTENANCE THERAPY; MALE; OPIATE ADDICTION; PSYCHOMOTOR PERFORMANCE; RATING SCALE; TREATMENT OUTCOME; VISUAL ANALOG SCALE;

ADULT; ANALGESICS, OPIOID; HEART RATE; HUMANS; HYDROMORPHONE; MIDDLE AGED; NALOXONE; NARCOTIC ANTAGONISTS; NARCOTICS; OPIOID-RELATED DISORDERS; TRAMADOL;

EID: 33745596604     PISSN: 10641297     EISSN: None     Source Type: Journal    
DOI: 10.1037/1064-1297.14.2.109     Document Type: Article

References (39)

1. Bamigbade, T. A., Davidson, C., Langford, R. M., & Stamford, J. A. (1997). Actions of tramadol, its enantiomers and principal metabolite, O-desmethyltramadol, on serotonin (5-HT) efflux and uptake in the rat dorsal raphe nucleus. British Journal of Anaesthesia, 79, 352-356.
2. Benetton, S. A., Borges, V. M., Chang, T. K., & McErlane, K. M. (2004). Role of individual human cytochrome P450 enzymes in the in vitro metabolism of hydromorphone. Xenobiotica, 34, 335-344.
3. Bodalia, B., McDonald, C. J., Smith, K. J., O'Brien, C., & Cousens, L. (2003). A comparison of the pharmacokinetics, clinical efficacy, and tolerability of once-daily tramadol tablets with normal release tramadol capsules. Journal of Pain and Symptom Management, 25(2), 142-149.
4. Cami, J., Lamas, X., & Farre, M. (1994). Acute effects of tramadol in methadone-maintained volunteers. Drugs, 47(Suppl. 1), 39-43.
5. Cicero, T. J., Adams, E. H., Geller, A., Inciardi, J. A., Munoz, A., Schnoll, S. H., et al. (1999). A postmarketing surveillance program to monitor Ultram (tramadol hydrochloride) abuse in the United States. Drug and Alcohol Dependence, 57(1), 7-22.
6. Collart, L., Luthy, C., Favario-Constantin, C., & Dayer, P. (1993). Duality of the analgesic effect of tramadol in humans. Schweizerische Medizinische Wochenschrift. Journal Suisse De Medecine, 123, 2241-2243.
7. Desmeules, J. A., Piguet, V., Collart, L., & Dayer, P. (1996). Contribution of monoaminergic modulation to the analgesic effect of tramadol. British Journal of Clinical Pharmacology, 41(1), 7-12.
8. Driessen, B., & Reimann, W. (1992). Interaction of the central analgesic, tramadol, with the uptake and release of 5-hydroxytryptamine in the rat brain in vitro. British Journal of Pharmacology, 105, 147-151.
9. Driessen, B., Reimann, W., & Giertz, H. (1993). Effects of the central analgesic tramadol on the uptake and release of noradrenaline and dopamine in vitro. British Journal of Pharmacology, 108, 806-811.
10. Filip, M., Wydra, K., Inan, S. Y., Dziedzicka-Wasylewska, M., & Przegalinski, E. (2004). Opioid and monoamine systems mediate the discriminative stimulus of tramadol in rats. European Journal of Pharmacology, 498(1-3), 143-151.
11. Friderichs, E., Felgenhauer, F., Jongschaap, P., & Osterloh, G. (1978). Pharmakologische Untersuchungen zur Analgesie, Abhängigkeits- und Toleranzentwicklung von Tramadol, einem stark wirksamen Analgetikum [Pharmacological studies on analgesia, dependence on and tolerance of tramadol, a potent analgesic drug]. Arzneimittelforschung, 28(1a), 122-134.
12. Gillen, C., Haurand, M., Kobelt, D. J., & Wnendt, S. (2000). Affinity, potency and efficacy of tramadol and its metabolites at the cloned human mu-opioid receptor. Naunyn-Schmiedeberg's Archives of Pharmacology, 362(2), 116-121.
13. Gutstein, H. B., & Akil, H. (2001). Opioid analgesics. In J. G. Hardman, L. E. Limbird, & A. Gilman (Eds.), Goodman & Gilman's the pharmacological basis of therapeutics (10th ed., pp. 569-619). New York: McGraw-Hill.
14. Knisely, J. S., Campbell, E. D., Dawson, K. S., & Schnoll, S. H. (2002). Tramadol post-marketing surveillance in health care professionals. Drug and Alcohol Dependence, 68(1), 15-22.
15. Kolb, L., & Himmelsbach, C. K. (1938). Clinical studies of drug addiction: III. A critical review of withdrawal treatments with methods of evaluating abstinence syndromes. American Journal of Psychiatry, 94, 759-799.
16. Laugesen, S., Enggaard, T. P., Pedersen, R. S., Sindrup, S. H., & Brosen, K. (2005). Paroxetine, a cytochrome P450 2D6 inhibitor, diminishes the stereoselective O-demethylation and reduces the hypoalgesic effect of tramadol. Clinical Pharmacology and Therapeutics, 77, 312-323.
17. Lehmann, K. A., Kratzenberg, U., Schroeder-Bark, B., & Horrichs-Haermeyer, G. (1990). Postoperative patient-controlled analgesia with tramadol: Analgesic efficacy and minimum effective concentrations. Clinical Journal of Pain, 6(3), 212-220.
18. McLeod, D., Griffiths, R. R., Bigelow, G. E., & Yingling, J. (1982). An automated version of the Digit Symbol Substitution Test (DSST). Behavior Research Methods & Instrumentation, 14, 463-466.
19. Miranda, H. F., & Pinardi, G. (1998). Antinociception, tolerance, and physical dependence comparison between morphine and tramadol. Pharmacology, Biochemistry and Behavior, 61, 357-360.
20. Preston, K. L., Bigelow, G. E., & Liebson, I. A. (1988). Butorphanol-precipitated withdrawal in opioid-dependent human volunteers. Journal of Pharmacology and Experimental Therapeutics, 246, 441-448.
21. Preston, K. L., Bigelow, G. E., & Liebson, I. A. (1989). Antagonist effects of nalbuphine in opioid-dependent human volunteers. Journal of Pharmacology and Experimental Therapeutics, 248, 929-937.
22. Preston, K. L., Bigelow, G. E., & Liebson, I. A. (1990). Discrimination of butorphanol and nalbuphine in opioid-dependent humans. Pharmacology, Biochemistry and Behavior, 37, 511-522.
23. Preston, K. L., Jasinski, D. R., & Testa, M. (1991). Abuse potential and pharmacological comparison of tramadol and morphine. Drug and Alcohol Dependence, 27(1), 7-17.
24. Raffa, R. B., Friderichs, E., Reimann, W., Shank, R. P., Codd, E. E., & Vaught, J. L. (1992). Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an "atypical" opioid analgesic. Journal of Pharmacology and Experimental Therapeutics, 260, 275-285.
25. Raffa, R. B., Friderichs, E., Reimann, W., Shank, R. P., Codd, E. E., Vaught, J. L., et al. (1993). Complementary and synergistic antinociceptive interaction between the enantiomers of tramadol. Journal of Pharmacology and Experimental Therapeutics, 267, 331-340.
26. Reisine, T., & Pasternak, G. (1996). Opioid analgesics and antagonists. In J. G. Hardman, L. E. Limbird, P. B. Molinoff, R. W. Ruddon, & A. G. Gilman (Eds.), Goodman & Gilman's the pharmacological basis of therapeutics (9th ed., pp. 521-555). New York: McGraw-Hill.
27. Ren, Y. H., & Zheng, J. W. (2000). Influence of tramadol on morphine discriminative behavior in rats. Acta Pharmacologica Sinica, 21, 924-926.
28. Schuh, K. J., Walsh, S. L., Bigelow, G. E., Preston, K. L., & Stitzer, M. L. (1996). Buprenorphine, morphine and naloxone effects during ascending morphine maintenance in humans. Journal of Pharmacology and Experimental Therapeutics, 278, 836-846.
29. Sobey, P. W., Parran, T. V., Jr., Grey, S. F., Adelman, C. L., & Yu, J. (2003). The use of tramadol for acute heroin withdrawal: A comparison to clonidine. Journal of Addictive Diseases, 22(4), 13-25.
30. Spitzer, R. L., Williams, J. B., Gibbon, M., & First, M. B. (1992) The Structured Clinical Interview for DSM-III-R (SCID): I. History, rationale, and description. Archives of General Psychiatry, 49, 624-629.
31. Strain, E. C., Preston, K. L., Liebson, I. A., & Bigelow, G. E. (1993). Precipitated withdrawal by pentazocine in methadone-maintained volunteers. Journal of Pharmacology and Experimental Therapeutics, 267, 624-634.
32. Strain, E. C., Preston, K. L., Liebson, I. A., & Bigelow, G. E. (1995). Buprenorphine effects in methadone-maintained volunteers: Effects at two hours after methadone. Journal of Pharmacology and Experimental Therapeutics, 272, 628-638.
33. Tamaskar, R., Parran, T. V., Jr., Heggi, A., Brateanu, A., Rabb, M., & Yu, J. (2003). Tramadol versus buprenorphine for the treatment of opiate withdrawal: A retrospective cohort control study. Journal of Addictive Diseases, 22(4), 5-12.
34. Valle, M., Garrido, M. J., Pavon, J. M., Calvo, R., & Troconiz, I. F. (2000). Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effects of main active metabolites of tramadol, (+)-O-desmethyltramadol and (-)-O-desmethyltramadol, in rats. Journal of Pharmacology and Experimental Therapeutics, 293, 646-653.
35. Walsh, S. L., June, H. L., Schuh, K. J., Preston, K. L., Bigelow, G. E., & Stitzer, M. L. (1995). Effects of buprenorphine and methadone in methadone-maintained subjects. Psychopharmacology (Berlin), 119(3), 268-276.
36. Woody, G. E., Senay, E. C., Geller, A., Adams, E. H., Inciardi, J. A., Schnoll, S., et al. (2003). An independent assessment of MEDWatch reporting for abuse/dependence and withdrawal from Ultram (tramadol hydrochloride). Drug and Alcohol Dependence, 72(2), 163-168.
37. Wu, D., Otton, S. V., Sproule, B. A., Busto, U., Inaba, T., Kalow, W., et al. (1993). Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone. British Journal of Clinical Pharmacology, 35(1), 30-34.
38. Yanagita, T. (1978). Drug dependence potential of 1-(m-methoxyphenyl)-2- dimethylaminomethyl)-cyclohexan-1-ol hydrochloride (tramadol) tested in monkeys. Arzneimittelforschung, 28(1a), 158-163.
39. Zanarini, M. C., Skodol, A. E., Bender, D., Dolan, R., Sanislow, C., Schaefer, E., et al. (2000). The Collaborative Longitudinal Personality Disorders Study: Reliability of Axis I and II diagnoses. Journal of Personality Disorders, 14, 291-299.